OUR RELEASES

List of publications

Lähteenvuo M, Tanskanen A, Taipale H. Real-World Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry. Feb 28, 2018. doi:10.1001/jamapsychiatry.2017.4711
Strongman H, Christopher S, Majak M, Williams R, Bahmanyar S, Linder M, Heintjes EM, Bennett D, Korhonen P, Hoti F. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Research and Care 2018;6:e000481. doi: 10.1136/bmjdrc-2017-000481
Johansson G, Mushnikov V, Bäckström T, Engström A, Khalid JM, Wall J, Hoti F. Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study. BMC Pulmonary Medicine (2018) 18:17 DOI 10.1186/s12890-018-0573-0
Taipale H, Mittendorfer-Rutz E, Alexanderson K, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Tiihonen J. Antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia.
Schizophr Res. 2017 Dec 20. pii: S0920-9964(17)30762-4. doi: 10.1016/j.schres.2017.12.010. [Epub ahead of print]
PMID: 29274734
Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause. 2017 Nov 13. doi: 10.1097/GME.0000000000001023. [Epub ahead of print]
PMID: 29112596
Mehtälä J, Majak M, Taipale H, Tanskanen A, Tiihonen J, Mittendorfer-Rutz E, Sermon J, Leval A, Hoti F. Risk of Severe Bleeding in Patients with Myocardial Infarction Receiving Clopidogrel – Nationwide Registry Study from Finland. ICPE 2017, Montreal, Canada, 26-30 August, 2017.
Mehtälä J, Majak M, Taipale H, Tanskanen A, Tiihonen J, Mittendorfer-Rutz E, Sermon J, Leval A, Hoti F. Adjusting for unobserved disease severity using individuals as their own controls – an example from a schizophrenia study. ICPE 2017, Montreal, Canada, 26-30 August, 2017.
Hoti F, Mehtälä J, Khanfir H, Christopher S, Bennett D, Ye Y, Korhonen P. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. ICPE 2017, Montreal, Canada, 26-30 August, 2017.
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, Taipale H. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
JAMA Psychiatry. 2017 Jul 1;74(7):686-693. doi: 10.1001/jamapsychiatry.2017.1322.
PMID: 28593216
Tiihonen J, Tanskanen A, Hoti F, Vattulainen P, Taipale H, Mehtälä J, Lähteenvuo M. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study. Published in The Lance Psychiatry Volume 4, No. 7, p547–553, July 2017.
Strongman H, Korhonen P, Williams R, et al. Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Research and Care 2017;5:e000364. doi: 10.1136/bmjdrc-2016-000364.
Tiihonen J, Lähteenvuo M, Hoti F, Vattulainen P, Taipale H, Tanskanen A. Real-world effectiveness of antipsychotic treatments among patients with schizophrenia and affective symptoms. European Psychiatry, Volume 41, S386
Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, Lassila R, Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf. 2017 Mar 19: doi: 10.1002/pds.4194. [Epub ahead of print.]
Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Lower Death Risk for Vascular Dementia Than for Alzheimer's Disease With Postmenopausal Hormone Therapy Users. J Clin Endocrinol Metab. 2017 Mar 1;102(3):870-877. doi: 10.1210/jc.2016-3590. PMID: 27906568
Strandberg AY, Khanfir H, Mäkimattila S, Saukkonen T, Strandberg TE, Hoti F. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults. Ann Med. 2017 Jun;49(4):357-364. doi: 10.1080/07853890.2016.1278302. Epub 2017 Feb 10. PMID: 28042719
Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Lower Death Risk for Vascular Dementia than for Alzheimer's Disease with Postmenopausal Hormone Therapy Users. J Clin Endocrinol Metab. 2016 Dec 1:jc20163590. [Epub ahead of print]
Tiihonen J, Lähteenvuo M, Hoti F, Vattulainen P, Tanskanen A. Real-world effectiveness of pharmacological treatments in severe unipolar depression in a nationwide cohort of 123,712 patients. ACNP 55th Annual Meeting, December 4–8, 20162, Hollywood, Florida. Neuropsychopharmacology (2016) 41, S289–S454. Poster T115.
Prami T, Khanfir H, Deleskog A, Hasvold P, Kytö V, Reissell E, Airaksinen J. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. BMJ Open 2016;6:e012604.
Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause. 2016 Nov;23(11):1199-1203.
Prami T, Khanfir H, Deleskog A, Hasvold P, Kytö V, Reissell E, Airaksinen J. Age predicts initiation of and persistence with P2Y12 inhibitor treatment after acute coronary syndrome - results form a nationwide retrospective cohort in Finland. ESC Congress, Rome, Italy, 27-31 August, 2016.
Prami T, Khanfir H, Deleskog A, Hasvold P, Kytö V, Reissell E, Airaksinen J. Gender differences in oral antiplatelet treatment use - results from a nationwide cohort study of acute coronary syndrome patients in Finland. ESC Congress, Rome, Italy, 27-31 August, 2016.
Prami T, Långström D, Iso-Mustajärvi I, Sandler N. Contraindicated and off-label drug use in pediatric outpatietns in the Nordic countries. ICPE 32nd International Conference, Dublin, Ireland, 25-28 August, 2016.
Mushnikov V, Mehtälä J, Wentzell N, Kollhorst B, Schink T, Garbe E, Mountford W, Knox C, Kaufman E, Johansson G, Korhonen P, Hoti F. COPD Patients Initiating Roflumilast in Sweden, Germany and the United States: Findings from the Roflumilast PASS study. ICPE 32nd International Conference, Dublin, Ireland, 25-28 August, 2016.
Mehtälä J, Raatikainen P, Lassila R, Khanfir H, Korhonen P, Hoti F, Lehto M. The quality of warfarin therapy among atrial fibrillation patients in Finland - Results form the FinWAF registry. ICPE 32nd International Conference, Dublin, Ireland, 25-28 August, 2016.
Khanfir H, Korhonen P, Mäkimattila S, Hoti F. Adjusting for the Effect of Switching Basal Insulin Treatment on the Risk of First Severe Hypoglycaemia. ICPE 32nd International Conference, Dublin, Ireland, 25-28 August, 2016.
Korhonen P, Heintjes E M, Williams R, Hoti F, Christopher S, Majak M, Kool-Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. BMJ 2016;354:i3903.
Savolainen-Peltonen H, Tuomikoski P, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies. J Clin Endocrinol Metab 2016 Jul;101(7):2794-801.
Strandberg AY, Hoti FJ, Strandberg TE, Christopher S, Haukka J, Korhonen P. All-cause and cause-specific mortality among users of basal insulins NPH, detemir and glargine. PLoS One 11(3), 2016.
Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Vaginal estradiol use and the riskfor cardiovascular mortality. Hum Reprod 2016 Apr;31(4):804-9.
Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J Clin Endocrinol Metab. 2015 Dec; 100(12): 4588-94
Daumont MM, Juuti R, Hoeller C, Zagorska A, Mertano E, Korhonen P. Comparative effectiveness research of treatments for advanced melanoma in Europe using existing real-world data sources: A feasibility assessment. Society for Melanoma Research 2015 International Congress, San Francisco, US, 18-21 November, 2015
Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F,Lassila R, Raatikainen P. Risk Of Stroke, Bleeding And Mortality Is Strongly Associated With The Quality Of Warfarin Therapy. Results From The FinWAF Registry With 54568 Patients. American Heart Association's Scientific Session 2015, Orlando, US, 12-16 November, 2015
Raatikainen P, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Lassila R, Lehto M. Poor Quality of Warfarin Therapy is Associated With Elevated Risk Of Myocardial Infarction in Patients With Atrial Fibrillation. Results From the FinWAF Registry With 54568 Patients. American Heart Association's Scientific Session 2015, Orlando, US, 12-16 November, 2015 
Långström D, Iso-Mustajärvi I, Sandler N, Prami T. Children's medication in the Nordic countries - Survey on national administrative register data. ISPOR 18th Annual European Congress, Milan, Italy, 7-11 November 2015
Mikkola TS, Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015 Sep;22(9):976-83
Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women’s Health Initiative: A cohort study. Maturitas. 2015 Jul;81(3):384-8
Tiihonen J, Lehti M, Aaltonen M, Kivivuori J, Kautiainen H, Virta L, Hoti F, Tanskanen A, Korhonen P. Psychotropic drugs and homicide: a prospective cohort study from Finland. World Psychiatry. 2015 Jun;14(2):245-7
Korhonen P, Heintjes EM, Williams R, Hoti F, Christopher S, Majak M, Houweling L, Strongman H, Linder M, Dolin P, Bahmanyar S. Bladder cancer risk in relation to exposure to pioglitazone among patients with T2DM in the Pan European Multi­Database Bladder Cancer Risk Characterisation Study. American Diabetes Association's 75th Scientific Session, Boston, USA, 5-9 June, 2015
Korhonen P, Kuoppamäki M, Prami T, Hoti F, Cristopher S, Ellmèn J, Aho V, Vahteristo M, Pukkala E, Haukka J. Entacapone and prostate cancer risk in patients with Parkinson's disease. Mov Disord. 2015 Apr 15;30(5):724-8
Tuomikoski P, Lyytinen H, Korhonen P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola S. Coronary heart disease mortality and hormone therapy before and after the women's health initiative. Obstet Gynecol. 2014; 124:947-953
Sulamaa A, Prami T, Sipilä R, Linna M, Hahl J, Miettinen T, Leppä E, Haukka J, Tuomilehto J, Enlund H, Niskanen L, Korhonen P. Description of the permit process for a national registry study - implementation of the Current Care Guideline for diabetes mellitus as an example. Lääkärilehti. 2014, 46:3085-9
Hoti F, Vattulainen P, Mushnikov V, Saukkonen T, Korhonen P. Regional assessment of severe hypoglycemic coma events in Finland. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 Nov, 2014
Khalid JM, Mushnikov V, Vattulainen P, Johansson G, Korhonen P, Hoti F. Patients with COPD who initiate roflumilast in Sweden. ISPOR 17th Annual European Congress,Amsterdam, The Netherlands, 8-12 Nov, 2014
Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J. Entacapone does not increase prostate cancer risk of mortality in patients with Parkinson's disease. ISPOR 17th Annual European Congress, Amsterdam, the Netherlands, 8-12 Nov, 2014
Prami T, Sulamaa A, Sipilä R, Linna M, Hahl J, Miettinen T, Leppä E, Haukka J, Tuomilehto J, Enlund H, Niskanen L, Korhonen P. Uses of electronic patient information systems and national registers - Implementation of the clinical practice guideline and evaluation of costs and use of resources in patients with incident type 2 diabetes in Finland. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 8-12 Nov, 2014
Hoti F, Mushnikov V, Vattulainen P, Johansson G, Khalid JM, Korhonen P. Exacerbations and healthcare resource utilization among COPD patients in Sweden. ERS International Congress 2014, Munich, Germany, 6-10 Sep, 2014
Makimattila S, Hoti F, S. Christopher, J. Haukka, P. Korhonen, T. Saukkonen. Lower risk of mortality in patients with type 2 diabetes using insulin detemir or glargine compared to NPH: a propensity score-matched nationwide register study in Finland. ADA 74th Scientific Session, San Francisco, USA, 13-17 June, 2014
Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf. 2013 doi: 10.1002/pds.3534
Suokas JT, Suvisaari JM, Haukka J, Korhonen P, Tiihonen J. Description of long-term polypharmacy among schizophrenia outpatients. Soc Psychiatry Psychiatr Epidemiol. 2012, DOI: 10.1007/s00127-012-0586-6
Korhonen P, Hoti F, Erästö P, Mäkimattila S, Saukkonen T, Haukka J. Risk of first severe hypoglycaemic (SH) coma event among patients with diabetes who initiate the use of detemir (IDet), gargine (IGla) and NPH insulins: a nationwide register-linkage study in Finland. Pharmacoepidemiology & Drug Safety. 2012; 21: (Suppl 3): 27-27, DOI: 10.1002/pds.3324
Mäkimattila S, Korhonen P, Haukka J, Hoti F, Pajunen P, Saukkonen T. Type of insulin and age are predictors of hospitalization due to severe hypoglycemia: The EpiHypo Study. Diabetes. 2012 Jun; 61:A101-A102; doi:10.2337/db12-378-655
Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry. 2012 May; 69(5):476-83
Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P. The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophr Res. 2011 Sep; 131(1-3): 260-1. Epub 2011 Jun 12
Korhonen P, Haukka J, Tayler M, Haddad PM, Patel MX, Tiihonen J. Rehospitalization risk and discontinuation of initial antipsychotic treatment after first hospital episode of schizophrenia. DIA's 23rd Annual Euromeeting, Geneva, Switzerland, March 2011
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. Am J Psyciatry. 2011 Jun; 168(6):603-9. Epub 2011 March 1
Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and statin usage - record linkage study. Int J Cancer. 2010 Jan 1;126(1):279-84. 
Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J. Incidence of cancer and antidepressant medication: record linkage study. Int J Cancer. 2010 Jan 1;126(1):285-96.
Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug 22;374(9690):620-7. 
Haukka J, Arffman M, Partonen T, Sihvo S, Elovainio M, Tiihonen J, Lönnqvist J, Keskimäki I. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort. Eur J Clin Pharmacol. 2009 Jul;65(7):715-20. 
Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):686-96. 
Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry. 2007 Jan;164(1):160-2. 
Are you interested in learning more about how our RWE solutions can help you in your drug development and surveillance? Our team of experts is eager to discuss your specific needs. To learn more, please contact us at office@epidresearch.com.